8-K/A: Celularity Amends Forbearance Agreements, Reprices and Issues New Warrants to Key Investors

Celularity Inc. has amended forbearance agreements with C. V. Starr & Co., Inc. and Resorts World Inc Pte Ltd, repricing existing warrants to lower exercise prices and issuing new warrants, signaling ongoing financial restructuring.

Summary

• Celularity Inc. filed an amendment to its Current Report on Form 8-K to include details on warrants issued to C. V. Starr & Co., Inc. (Starr) and Resorts World Inc Pte Ltd (RWI).
• The actions stem from binding term sheets entered into on February 12, 2025, which amend forbearance agreements originally established on March 13, 2024.
• Outstanding warrants issued to Starr were repriced, setting their exercise price at $1.692 per share of common stock.
• Outstanding warrants issued to RWI were repriced, setting their exercise price at $2.844 per share of common stock.
• A new warrant was issued to Starr to purchase up to 100,000 shares of Class A Common Stock at an exercise price of $1.692 per share, with a five-year term from its February 12, 2025 issuance date.
• A new warrant was issued to RWI to purchase up to 500,000 shares of Class A Common Stock at an exercise price of $2.844 per share, with a five-year term from its July 24, 2025 issuance date.
• An Amended and Restated RWI Warrant (Tranche 2) dated January 16, 2024, for 1,350,000 shares at an exercise price of $2.844, is exercisable upon meeting 'Initial Exercise Conditions' including CFIUS Clearance, a six-month waiting period, and an 'Exchange Cap Condition'.
• The 'Exchange Cap Condition' for the RWI Tranche 2 warrant requires that the aggregate shares issued do not exceed 19.9% of outstanding Class A Common Stock, or stockholder approval, or an exercise price equal to or exceeding the Loan Date Minimum Price of $0.24898 per share.
• An Amended and Restated RWI Warrant dated March 13, 2024, for 300,000 shares at an exercise price of $2.844, has a termination date of June 20, 2028.

Sentiment

Score: 3

Explanation: The repricing of warrants to lower exercise prices and the context of forbearance agreements suggest significant financial challenges and a reduced valuation, indicating a negative sentiment for the company's stock.

Positives

• The amendment of forbearance agreements and issuance of new warrants indicate continued support and engagement from key investors, Starr and RWI.
• The agreements provide a structured pathway for potential future capital infusion through warrant exercises.

Negatives

• The repricing of existing warrants to significantly lower exercise prices ($1.692 for Starr, $2.844 for RWI) suggests a reduced valuation of the company's stock.
• The issuance of new warrants at these lower exercise prices poses a risk of substantial dilution for existing shareholders if exercised.
• The necessity of forbearance agreements in the first place indicates underlying financial challenges or distress.

Risks

• The securities evidenced by the warrants have not been registered under the Securities Act of 1933, restricting their sale, transfer, assignment, or hypothecation without an effective registration statement or an applicable exemption.
• Acquisition of Class A Common Stock pursuant to the warrants involves a high degree of risk, and holders may suffer a complete loss of their investment.
• The value of the Class A Common Stock to be purchased upon exercise of the warrants may significantly depreciate over time, with no assurances of value increase.
• Exercise of certain RWI warrants is subject to 'Initial Exercise Conditions,' including CFIUS Clearance and an 'Exchange Cap Condition,' which could delay or prevent their exercise.
• The 'Exchange Cap Condition' may require stockholder approval if the exercise price falls below a certain threshold, introducing uncertainty and potential delays.

Future Outlook

The filing primarily details past and current warrant agreements and repricings, with future implications tied to the exercise of these warrants. The exercise of certain RWI warrants is contingent on meeting specific 'Initial Exercise Conditions,' including CFIUS Clearance and an 'Exchange Cap Condition,' which could influence future capital inflows and share structure.

Industry Context

The repricing of warrants and the underlying forbearance agreements suggest that Celularity, a company likely in the capital-intensive biotechnology sector, is navigating financial challenges. Such adjustments are common for development-stage companies that require ongoing funding and may face pressure on their stock valuation, often leading to more favorable terms for investors to secure continued support.

Corporate Governance

Related Party Transactions

• The warrant agreements and amendments are with C. V. Starr & Co., Inc. and Resorts World Inc Pte Ltd, who are significant investors and creditors, making these related party transactions.

Stakeholder Impact

• Shareholders face potential dilution from the exercise of warrants at lower prices, which could decrease the value of their existing holdings.
• Investors (Starr and RWI) benefit from repriced warrants and new warrant issuances at more favorable exercise prices, reflecting a restructuring of their investment and continued support for the company.
• The company gains continued financial flexibility and support from key investors through these agreements, which are crucial given the context of forbearance.

Next Steps

• Holders of the warrants may exercise their rights to purchase Class A Common Stock, subject to the terms and conditions outlined in each warrant agreement.
• Celularity Inc. will need to ensure compliance with the 'Exchange Cap Condition' for the RWI Tranche 2 warrant, potentially requiring stockholder approval.
• CFIUS Clearance must be obtained for the RWI Tranche 2 warrant to become fully exercisable.

Key Dates

Recommendation

The repricing of warrants to significantly lower exercise prices and the issuance of new warrants at these reduced prices indicate a deteriorating valuation and potential substantial dilution for existing shareholders. The underlying forbearance agreements suggest ongoing financial challenges. While these agreements provide some short-term stability, the terms of the warrants reflect a less favorable outlook for the company's stock value, making it a less attractive investment at this time.

Keywords

Celularity Inc., Warrants, Forbearance Agreement, Stock Repricing, Dilution, SEC Filing, Capital Raise, Biotechnology, Financial Restructuring, Class A Common Stock, CFIUS Clearance, Nasdaq